BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:The study of PARP inhibitor resistance using genetically engineere
 d mouse models for BRCA1/2-mutated breast cancer
DTSTART:20210218T121500
DTEND:20210218T133000
DTSTAMP:20260505T010055Z
UID:f97ef5237a612248961b3d51bf254623822958b20a13b8e06ef65cd5
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Sven Rottenberg\nA Lola and John Grace Distinguised Lect
 ure in Cancer Research\nOrdinarily this seminar will also be televised to 
 AGORA + Geneva University => however at this time it will only be via ZOOM
 .\n\nSven Rottenberg\, DVM\, PhD\, Dipl. ECVP\nInstitute of Animal Patholo
 gy\, Vetsuisse Faculty\, University of Bern\, Switzerland\n\nFrom 1999-200
 4 Sven Rottenberg received a dual education in veterinary pathology (Dipl.
  ECVP) and molecular biology (PhD) at the University of Bern (Switzerland)
 . In 2004 he joined the group of Piet Borst at the Netherlands Cancer Inst
 itute (NKI) in Amsterdam where he became a tenured staff member (associate
  professor level) in 2012. At the NKI Sven Rottenberg established a new re
 search focus: the study of anti-cancer drug resistance using genetically e
 ngineered mouse models (GEMMs) of human cancer. In 2014 he returned to the
  University of Bern as head of the Institute of Animal Pathology. The focu
 s of the Rottenberg group is to understand the underlying mechanisms of re
 sistance to anti-cancer therapies\, including both radio- and chemotherapy
 . His group has identified various mechanisms of PARP inhibitor resistance
  (e.g. loss of PARG or a dysfunctional 53BP1-REV7-shieldin-CST pathway)\, 
 and thereby generated novel insights into basic mechanisms of the DNA dama
 ge response. In addition\, using functional genetic screens in haploid cel
 ls\, his group found LRRC8A/D proteins to be relevant factors in platinum 
 drug resistance and ERCC6L2 as a useful marker to predict radiotherapy res
 ponse. Moreover\, the Rottenberg group has generated unique mouse models t
 o study residual disease and they have pioneered the use of 3D cancer orga
 noids to study therapy escape.\n\nThe research of the Rottenberg group is 
 supported by the Swiss National Science Foundation\, the European Research
  Council\, the Swiss Krebsliga\, and the Wilhelm Sander Foundation.\n 
LOCATION:ZOOM
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR